Everolimus with bevacizumab versus interferon alfa-2a plus bevacizumab as first-line therapy in patients with metastatic clear cell renal cell carcinoma.

First Line Therapy ◽

666P Pembrolizumab (pembro) monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC): Results after a minimum of 41 months of follow-up from KEYNOTE-427 cohort A

Annals of Oncology ◽

10.1016/j.annonc.2021.08.062 ◽

2021 ◽

Vol 32 ◽

pp. S691-S692

Author(s):

D.F. McDermott ◽

J-L. Lee ◽

G.A. Bjarnason ◽

J. Larkin ◽

R. Gafanov ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Clear Cell ◽

First Line ◽

First Line Therapy ◽

1919 NEUTROPHIL-TO-LYMPHOCYTE RATIO REDUCTION AS A SURROGATE MARKER OF PROGNOSIS IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA RECEIVING SUNITINIB AS FIRST-LINE THERAPY

The Journal of Urology ◽

10.1016/j.juro.2013.02.2338 ◽

2013 ◽

Vol 189 (4S) ◽

Cited By ~ 1

Author(s):

Yong Hyun Park ◽

Young Ju Lee ◽

Ja Hyeon Ku ◽

Cheol Kwak ◽

Hyeon Hoe Kim

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Clear Cell ◽

Surrogate Marker ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Ratio Reduction

Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.4500 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 4500-4500 ◽

Cited By ~ 49

Author(s):

David F. McDermott ◽

Jae-Lyun Lee ◽

Cezary Szczylik ◽

Frede Donskov ◽

Jahangeer Malik ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Clear Cell ◽

First Line ◽

First Line Therapy ◽

Post-treatment neutrophil-to-lymphocyte ratio in predicting prognosis in patients with metastatic clear cell renal cell carcinoma receiving sunitinib as first line therapy

SpringerPlus ◽

10.1186/2193-1801-3-243 ◽

2014 ◽

Vol 3 (1) ◽

pp. 243 ◽

Cited By ~ 22

Author(s):

Yong Park ◽

Ja Ku ◽

Cheol Kwak ◽

Hyeon Kim

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Clear Cell ◽

Post Treatment ◽

First Line ◽

Lymphocyte Ratio ◽

First Line Therapy ◽

702O Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from the COSMIC-021 study

Annals of Oncology ◽

10.1016/j.annonc.2020.08.774 ◽

2020 ◽

Vol 31 ◽

pp. S554

Author(s):

S. Pal ◽

C-K. Tsao ◽

C. Suarez ◽

W. Kelly ◽

L. Pagliaro ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Clear Cell ◽

First Line ◽

First Line Therapy ◽

Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy

Targeted Oncology ◽

10.1007/s11523-017-0498-1 ◽

2017 ◽

Vol 12 (4) ◽

pp. 487-494 ◽

Cited By ~ 16

Author(s):

Solène-Florence Kammerer-Jacquet ◽

Sarah Medane ◽

Karim Bensalah ◽

Jean-Christophe Bernhard ◽

Mokrane Yacoub ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Clear Cell ◽

First Line ◽

First Line Therapy ◽

Comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy

The Korean Journal of Internal Medicine ◽

10.3904/kjim.2018.064 ◽

2020 ◽

Vol 35 (1) ◽

pp. 185-193

Author(s):

In Hee Lee ◽

Byung Woog Kang ◽

Jong Gwang Kim ◽

Woo Kyun Bae ◽

Myung Seo Ki ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Risk Stratification ◽

Cell Carcinoma ◽

Renal Cell ◽

Clear Cell ◽

First Line ◽

First Line Therapy ◽

KEYNOTE-427 cohort A: Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC)

Annals of Oncology ◽

10.1093/annonc/mdy283.080 ◽

2018 ◽

Vol 29 ◽

pp. viii307 ◽

Cited By ~ 5

Author(s):

F. Donskov ◽

D.F. McDermott ◽

J.L. Lee ◽

C. Szczylik ◽

J. Malik ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Clear Cell ◽

First Line ◽

First Line Therapy ◽

662P Pembrolizumab (pembro) monotherapy as first-line therapy in advanced non–clear cell renal cell carcinoma (nccRCC): Results after a minimum of 34 months of follow-up from KEYNOTE-427 cohort B

Annals of Oncology ◽

10.1016/j.annonc.2021.08.058 ◽

2021 ◽

Vol 32 ◽

pp. S687

Author(s):

J-L. Lee ◽

D.F. McDermott ◽

M. Ziobro ◽

C. Suarez ◽

P. Langiewicz ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Clear Cell ◽

First Line ◽

First Line Therapy ◽

3002 Final quality of life (QOL) results with geographical analysis for sunitinib versus interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)70601-9 ◽

2009 ◽

Vol 7 (2) ◽

pp. 176 ◽

Cited By ~ 2

Author(s):

D. Cella ◽

M.D. Michaelson ◽

A.G. Bushmakin ◽

J.C. Cappelleri ◽

C. Charbonneau ◽

...

Keyword(s):

Quality Of Life ◽

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

Interferon Alfa ◽

First Line ◽

First Line Therapy ◽